Table 1.
Baseline associations between F2-isoprostanes tertiles and covariates by sex. Health ABC study (1997–98), N=726.
| MEN: | Tertile 1 n=119 <41.0 pg/ml |
Tertile 2 n=122 41.0–57.8 pg/ml |
Tertile 3 n=119 >57.8 pg/ml |
p-value |
|---|---|---|---|---|
|
Demographics:
| ||||
| Age, years b | 73.3 (72.8, 73.8) | 74.2 (73.7, 74.7) | 73.8 (73.3, 74.3) | 0.04 |
| Race, n (%): | ||||
| White | 57 (47.9) | 58 (47.5) | 64 (53.8) | 0.56 |
| Black | 62 (52.1) | 64 (52.5) | 55 (46.2) | |
| Clinic Site: | ||||
| Memphis | 59 (49.6) | 55 (45.1) | 65 (54.6) | 0.33 |
| Pittsburgh | 60 (50.4) | 67 (54.9) | 54 (45.4) | |
|
| ||||
|
Medication use:
| ||||
| Statin use, n(%) | 10 (8.4) | 16 (13.1) | 17 (14.3) | 0.32 |
| Aspirin use, n(%) | 47 (39.5) | 58 (47.5) | 52 (43.7) | 0.45 |
|
| ||||
|
Laboratory measures:
| ||||
| Total cholesterol, mg/dl b | 192.1 (186.2, 198.0) | 195.5 (189.5, 201.6) | 195.1 (189.0, 201.3) | 0.68 |
| HDL, mg/dl b | 44.5 (42.1, 46.8) | 49.5 (47.1, 51.9) | 50.2 (47.7, 52.6) | 0.002 |
| Triglycerides, mg/dla | 120.1 (110.6, 130.3) | 117.6 (108.1, 127.8) | 128.8 (118.3, 140.2) | 0.27 |
| CRP, mg/La | 1.8 (1.6, 2.1) | 1.8 (1.5, 2.1) | 1.6 (1.4, 1.9) | 0.72 |
| Adiponectin, μg/mla | 6.7 (6.0, 7.4) | 8.0 (7.2, 8.9) | 9.2 (8.2, 10.2) | <0.001 |
| PAI-1, ng/mla | 20.6 (18.2, 23.4) | 20.7 (18.1 23.5) | 22.1 (19.3, 25.2) | 0.71 |
| Leptin, ng/mla | 5.1 (4.4, 6.0) | 5.4 (4.6, 6.4) | 7.0 (5.9, 8.3) | 0.02 |
| Interleukin-6, pg/mla | 1.9 (1.7, 2.1) | 2.1 (1.9, 2.3) | 2.2 (2.0. 2.5) | 0.09 |
| TNF-α, pg/mla | 3.2 (2.9, 3.4) | 3.3 (3.0, 3.5) | 3.6 (3.4, 3.9) | 0.01 |
|
| ||||
|
Comorbid Conditions:
| ||||
| Diabetes (Type 2) | 24 (20.2) | 23 (18.9) | 20 (16.8) | 0.80 |
| Hypertension | 65 (54.6) | 74 (60.7) | 84 (70.6) | 0.04 |
| Coronary Heart Disease | 16 (13.5) | 31 (25.4) | 37 (31.1) | 0.005 |
| WOMEN: | Tertile 1 n=120 <50.6 pg/ml |
Tertile 2 n=125 50.6–75.5 pg/ml |
Tertile 3 n=121 >75.5 pg/ml |
p-value |
|---|---|---|---|---|
|
Demographics:
| ||||
| Age, years b | 73.1 (72.6, 73.7) | 73.6 (73.1, 74.1) | 73.9 (73.4, 74.5) | 0.11 |
| Race, n (%): | ||||
| White | 47 (39.2) | 59 (47.2) | 77 (63.6) | <0.001 |
| Black | 73 (60.8) | 66 (52.8) | 44 (36.4) | |
| Clinic Site: | ||||
| Memphis | 54 (45.0) | 64 (51.2) | 64 (52.9) | 0.43 |
| Pittsburgh | 66 (55.0) | 61 (48.8) | 57 (47.1) | |
|
| ||||
|
Medication use:
| ||||
| Statin use, n(%) | 10 (8.3) | 17 (13.6) | 17 (14.1) | 0.32 |
| Aspirin use, n(%) | 30 (25.0) | 51 (40.8) | 51 (42.2) | 0.009 |
|
| ||||
|
Laboratory measures:
| ||||
| Total cholesterol, mg/dl b | 213.8 (207.2, 220.5) | 212.4 (205.7, 219.1) | 210.7 (203.9, 217.4) | 0.86 |
| HDL, mg/dl b | 60.6 (57.5, 63.8) | 59.4 (56.3, 62.5) | 61.9 (58.7, 65.1) | 0.54 |
| Triglycerides, mg/dla | 112.1 (103.3, 121.7) | 123.3 (113.6, 133.8) | 122.1 (112.4, 132.7) | 0.20 |
| CRP, mg/La | 1.8 (1.6, 2.1) | 2.0 (1.7, 2.3) | 2.2 (1.9, 2.6) | 0.09 |
| Adiponectin, μg/mla | 10.5 (9.6, 11.6) | 10.1 (9.1, 11.1) | 13.1 (11.9, 14.5) | <0.001 |
| PAI-1, ng/mla | 20.1 (17.5, 23.1) | 23.7 (20.7, 27.2) | 21.0 (18.3, 24.2) | 0.22 |
| Leptin, ng/mla | 12.8 (11.2, 14.7) | 17.6 (15.3, 20.2) | 20.0 (17.4, 23.1) | <0.001 |
| Interleukin-6, pg/mla | 1.8 (1.6, 2.0) | 1.8 (1.6, 2.0) | 2.0 (1.8, 2.3) | 0.30 |
| TNF-α, pg/mla | 2.8 (2.6, 3.0) | 3.1 (2.8, 3.3) | 3.3 (3.0, 3.7) | 0.01 |
|
| ||||
|
Comorbid Conditions n (%):
| ||||
| Diabetes (Type 2) | 22 (18.3) | 30 (24.0) | 18 (14.9) | 0.18 |
| Hypertension | 73 (60.8) | 87 (69.6) | 79 (65.3) | 0.35 |
| Coronary Heart Disease | 10 (8.3) | 18 (14.4) | 15 (12.4) | 0.33 |
a
geometric mean (95% CI) presented due to skewness and resulting log transformation
b
regular mean (95% CI)